CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support access to Tibsovo (ivosidenib), the world’s first-in-class IDH1 inhibitor used to treat leukemia. The initiative was launched this month by the Shanghai Life Oasis Public Service Center, with support from the Beijing Health Alliance Charitable Foundation. The program will establish drug distribution locations in 34 cities across China.
Tibsovo Background
Tibsovo was originally developed by US-based Agios Pharmaceuticals. In June 2018, CStone licensed the commercial and development rights for the drug in Greater China. The drug received approval in China in January 2022 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (r/r AML) with IDH1 mutations. Since its approval, first prescriptions have been issued, and the drug is now officially supplied to over 50 in-hospital and out-of-hospital DTP pharmacies in multiple provinces and cities across the country.-Fineline Info & Tech
